iTind
Minimally Invasive BPH Treatment
The iTind is a temporarily implanted nitinol device which delivers rapid and effective relief from BPH symptoms through a minimally invasive treatment.

The iTind device is inserted into the prostatic urethra under vision using a cystoscope and held in the right position through the anchoring leaflet. The device is designed to ensure easy and precise positioning. Once in place, the iTind expands and exerts continuous pressure on the prostatic urethra and the bladder neck at the 5, 7 and 12 o’clock positions.

Over the next five to seven days, the iTind remolds the tissue by creating three deep longitudinal channels through a localized ischemic response. These three channels then allow urine to flow better. Patients are able to return home during the 5-7 day treatment. After the implantation period of 5-7 days, the device is completely removed.
Clinical data demonstrate that the first generation TIND boasts a durability of three years, and powerful efficacy at 36 months is also demonstrated by the second-generation and commercially available iTind.

- Rapid and effective relief from BPH symptoms.²⁻⁵
- Lower risk profile than more invasive procedures.³⁻⁵
- Routinely catheter free procedure.³⁻⁴
- Preserves sexual and ejaculatory function.⁴⁻⁵
- No permanent implant resulting from the procedure.²⁻⁵
- Straightforward procedure.

**Clinical Evidence**

**Scientific Publications¹**

Porpiglia et al., 2018²
- Single-center prospective pilot study on first generation TIND.
- Study site: Turin, Italy.
- Number of patients: 32.
- Inclusion criteria: Age: > 50 years; PV < 60 ml; IPSS ≥ 10; Qmax ≤ 12 ml/s.

Chughtai et al., 2020⁴
- Multicenter randomized, controlled trial on second generation iTind.
- Study sites: USA, Canada.
- Number of patients: 175 (randomized 2:1 between iTind and sham).
- Inclusion criteria: Age ≥ 50 years; PV < 75 ml; IPSS ≥ 10; Qmax ≤ 12 ml/s.

Amparore et al., 2021³
- Multicenter prospective study on second generation iTind.
- Study sites: Italy, UK, Switzerland, Belgium, Hong Kong, Spain.
- Number of patients: 81.
- Inclusion criteria: No age restriction; PV < 75 ml; IPSS ≥ 10; Qmax ≤ 12 ml/s.

De Nunzio et al., 2021⁵ — An Interim Analysis after 6 Months
- Multicenter prospective study on second generation iTind.
- Study sites: Italy, Spain.
- Number of patients: 70.
- Inclusion criteria: No age restriction; PV < 120 ml; IPSS ≥ 10; Qmax < 12 ml/s.

¹Company sponsored trials under the responsibility of Medi-Tate.
³Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2021;24(2):349-357. doi:10.1038/s41391-020-00281-5. Note: Results shown were derived by per protocol analysis.
As medical knowledge is constantly growing, technical modifications or changes of the product design, product specifications, accessories and service offerings may be required.